<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964912</url>
  </required_header>
  <id_info>
    <org_study_id>CN162-001</org_study_id>
    <nct_id>NCT00964912</nct_id>
  </id_info>
  <brief_title>Single Dose Study of BMS-820836</brief_title>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of BMS-820836 after&#xD;
      single doses&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of BMS-820836 following single-dose administration</measure>
    <time_frame>Within 14 days of first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the single-dose pharmacokinetics of BMS-820836 and its N-demethylated metabolite BMS-821007</measure>
    <time_frame>Within 7 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamics of BMS-820836</measure>
    <time_frame>Within 48 hours of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 5)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 7)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 8)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 1, Panel 9)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 2, Panel A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-820836 (Part 2, Panel B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 0.025 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 0.1 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 0.25 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 0.5 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 1 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 5)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 2 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 3 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 7)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 5 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 8)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 8 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 9)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution, Oral, 0 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 1, Panel 1)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 2)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 3)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 4)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 5)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 6)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 7)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 8)</arm_group_label>
    <arm_group_label>BMS-820836 (Part 1, Panel 9)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 3 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 2, Panel A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-820836</intervention_name>
    <description>Oral Solution, Oral, 0.5 mg, single dose, one dose</description>
    <arm_group_label>BMS-820836 (Part 2, Panel B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive and weight ≥ 50 kg&#xD;
&#xD;
          -  Right-handed, non-ambidextrous subjects for Part 2&#xD;
&#xD;
          -  Men and women, ages 18 to 55 years, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) who are unwilling or unable to use an&#xD;
             acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks&#xD;
             after the last dose of investigational product&#xD;
&#xD;
          -  WOCBP using a prohibited contraceptive method&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Sexually active fertile men not using effective birth control if their partners are&#xD;
             WOCBP&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Current or recent (within 3 months) gastrointestinal disease&#xD;
&#xD;
          -  History of cholecystectomy&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration&#xD;
&#xD;
          -  Any gastrointestinal surgery that could impact the absorption of study drug&#xD;
&#xD;
          -  Donation of blood or plasma to a blood bank or in a clinical study (except a screening&#xD;
             visit) within 4 weeks of study drug administration&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of study drug administration&#xD;
&#xD;
          -  Inability to tolerate/swallow oral medication&#xD;
&#xD;
          -  Difficulty with venipuncture and/or poor venous access&#xD;
&#xD;
          -  Self-reported smokers&#xD;
&#xD;
          -  Recent (within 1 year) of psychostimulant use (cocaine, methylphenidate, amphetamines,&#xD;
             ecstasy)&#xD;
&#xD;
          -  Confirmed resting supine systolic blood pressure &gt; 130 mmHg&#xD;
&#xD;
          -  Confirmed resting supine diastolic blood pressure &gt; 80 mmHg&#xD;
&#xD;
          -  Confirmed QT value ≥ 500 msec&#xD;
&#xD;
          -  Confirmed QTc (Bazett) value ≥ 450 msec&#xD;
&#xD;
          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)&#xD;
&#xD;
          -  History of peppermint allergies&#xD;
&#xD;
          -  History of brain conditions (e.g. history of stroke, head trauma, etc.)&#xD;
&#xD;
          -  History of or current psychiatric conditions&#xD;
&#xD;
          -  History of claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

